CompletedPhase 2NCT04220307

A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Akeso
Principal Investigator
Ruihua Xu, MD
Sun Yat-sen University
Intervention
AK104(biological)
Enrollment
34 target
Eligibility
18-75 years · All sexes
Timeline
20202023

Study locations (1)

Collaborators

Akeso Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04220307 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials